Drug Trial Radar · NCT07890298
A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Dec 31, 2027
Study completion Jun 2028
Sponsor
- Lead sponsor
- Lumosa Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 88 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, open-label, single-arm, exploratory study to evaluate the intracranial arterial recanalization of multiple doses of LT3001 drug product in participant with acute ischemic stroke (AIS)
Conditions
- Acute Ischemic Stroke
Interventions
LT3001 Drug ProductDrug
Administered by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of successful recanalization at 24 hours after the 1st IP. Successful recanalization is defined as any improvement in Arterial Occlusive Lesion (AOL) score.Time frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taichung Medical University, Taichung
Taichung, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.